SAS Output

16-OCT-2019 6:10

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) 1 Y 1 MK-3475 (pembrolizumab) 56 31 15 9 4 3 0 02/06/2017 105 44
            31 15 9 4 3 0      
 
  S1607-MELAN, Adv, T-VEC, MK-3475 1 Y 1 T-VEC + MK-3475(pembrolizumab) 64 23 19 9 3 1 0 06/05/2018 69 27
            23 19 9 3 1 0      
 
  S1616-MELAN, Adv, Ipilimumab Nivolumab 1 Y 1 Ipilimumab 94 17 9 7 4 1 1 10/23/2017 232 95
        2 Nivolumab + Ipilimumab   50 34 22 15 3 2      
            67 43 29 19 4 3      
 
  S1801-Melan, Adv, Adj vs Neoadj Pembrolizumab 1 Y 1 Adjuvant Arm 556 29 29 25 12 6 0 02/15/2019 302 126
        2 Neoadjuvant Pembrolizumab   27 27 26 11 3 0      
            56 56 51 23 9 0      
 
    2 Y 3 Surgery 556 41 41 38 23 8 2 02/15/2019    
            41 41 38 23 8 2      
 
    3 Y 4 Post-Surgery Pembro 556 29 29 28 24 8 0 02/15/2019    
            29 29 28 24 8 0      
 
Yes EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 1 E Total Registrations   42 12 7 2 1 0 11/03/2015 289 122
            42 12 7 2 1 0      
 
    2 E Total Registrations   14 2 1 0 0 0 11/03/2015    
            14 2 1 0 0 0      
 
  EA6141-Melan, Avd, Nivolumab+Ipi Sargmostim 1 E Total Registrations   36 0 0 0 0 0 03/25/2016 209 82
            36 0 0 0 0 0      
 
No EA6174-Merkel, Adjuvant Pembrolizumab vs Observation 1 E Total Registrations   2 2 2 1 1 0 05/01/2019 114 64
            2 2 2 1 1 0